News about our Companies

Briteseed vs. Surgical Perspective

Briteseed has raised $46,250 in cofounder contributions; significant business plan awards, including $73,500 in cash; $1.15 million raised in seed round using a convertible note.

Admetsys Wins Top Prize at SXSW Hatch Pitch competition

At the Hatch pitch competition five companies came away victorious including Admetsys. The winners received first round interview at Entrepreneurs Roundtable Accelerator; slots in two other accelerators; credits for services from Microsoft and Amazon; entrepreneur office hours.

Fibralign beats 267 other startups at the 2014 MedTech Innovator competition

The Biobridge is an implant that has been shown to be able to guide the growth of new lymph channels. This technology can be used as an adjunct to existing treatments for the condition to hopefully improve outcomes. Fibralign has benefited from grants from the DoD and NSF to support a large animal study and develop production tools for making its initial product.

Fibralign set to bring new device option for secondary lymphedema

Fibralign's first product, BioBridge, is developed to address Secondary Lymphedema, a global chronic debilitating disease that affects over 120 million people and has no cure. The company successfully completed a large animal study that validated BioBridge-treated diseased lymphatic tissue. Fibralign is now preparing for 510(k) submission and a clinical study.